Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 5/20 | 0.32 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.32 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762872 | 0.86 | OXTR (0.42) | MAPTOXTRMAP4K1PTK2 | |
| SCHEMBL1763310 | 0.85 | MAPT (0.38) | MAPTMAP4K1PTK2C5AR1 | |
| SCHEMBL1762962 | 0.81 | DGAT1 (0.42) | MAPTALDH1A1SRCPTK2C5AR1 | |
| SCHEMBL1762608 | 0.81 | EIF2AK4 (0.39) | MAPTKDM4EHPGDSRCBTK | |
| SCHEMBL1762713 | 0.80 | DGAT1 (0.42) | MAPTALDH1A1HPGDPTK2C5AR1 | |
| SCHEMBL1762583 | 0.79 | PTK2 (0.53) | MAPTPTK2 | |
| SCHEMBL1762893 | 0.79 | PTK2 (0.39) | MAPTALDH1A1HPGDLYNSRC | |
| SCHEMBL1762602 | 0.78 | C5AR1 (0.37) | MAPTPTK2C5AR1 | |
| SCHEMBL1762743 | 0.77 | MCHR1 (0.37) | MAPTKDM4EALDH1A1HPGDPTK2 | |
| SCHEMBL1762891 | 0.77 | MAPT (0.37) | MAPTHPGDPTK2C5AR1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633193-B2 | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-05-19 | — | — | US | disclosed |
| US-7906528-B2 | Such as 5-(2,6-diethyl-phenyl)-1H-pyrrolo[2,3-C]pyridine, which binds C5a receptors with high affinity; for treatment of inflammatory, cardiovascular, and immune system disorders; kits | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-15 | — | — | US | disclosed |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | NEUROGEN CORPORATION (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118273-A1 | PYRROLO-PYRIDINE, PYRROLO-PYRIMIDINE AND RELATED HETEROCYCLIC COMPOUNDS | C5AR1, C5AR2, C3AR1 | MAPT 4578/4885KDM4E 2304/4885ALDH1A1 3200/4885 |
| US-20080267887-A1 | Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds | C5AR1, C5AR2, C3AR1 | MAPT 4578/4885KDM4E 2304/4885ALDH1A1 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.